LAVA Therapeutics N.V. (LVTX) annual balance sheet — 6-year assets, liabilities & equity history
| Total Current Assets | 51.91M | 79.3M | 98.9M | 140.53M | 136.5M | 18.22M | 7.62M |
| Cash & Short-Term Investments | 49.66M | 76.58M | 95.57M | 132.87M | 133.2M | 15.82M | 7.34M |
| Cash Only | 49.66M | 35.02M | 44.23M | 100.33M | 90.87M | 15.82M | 7.34M |
| Short-Term Investments | 0 | 41.56M | 51.34M | 32.53M | 42.33M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 1.7M | 3.25M | 734K | 1.14M | 69K |
| Days Sales Outstanding | - | - | 91.61 | 61.25 | 50.08 | 111.05 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 2.1M | 1.65M | 1.63M | 4.41M | 0 | 1.15M | 151K |
| Total Non-Current Assets | 10K | 1.53M | 2.81M | 2.89M | 2.74M | 2.26M | 1.18M |
| Property, Plant & Equipment | 0 | 1.44M | 2.49M | 2.08M | 1.95M | 1.5M | 1.15M |
| Fixed Asset Turnover | 7.21x | 8.30x | 2.71x | 9.31x | 2.75x | 2.51x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 10K | 91K | 319K | 809K | 796K | 769K | 30K |
| Total Assets | 51.91M | 80.83M | 101.71M | 143.43M | 139.25M | 20.49M | 8.8M |
| Asset Turnover | 0.08x | 0.15x | 0.07x | 0.14x | 0.04x | 0.18x | - |
| Asset Growth % | -120.79% | -20.53% | -29.08% | 3% | 579.72% | 132.87% | - |
| Total Current Liabilities | 4.23M | 18.01M | 14.94M | 21.95M | 11.25M | 7.33M | 1.42M |
| Accounts Payable | 1.7M | 2.72M | 4.45M | 3.96M | 2.55M | 934K | 422K |
| Days Payables Outstanding | 27.39 | - | 466.05 | - | - | 21.71 | 18.45 |
| Short-Term Debt | 0 | 4.89M | 5.28M | 4.64M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 35M | 0 | 0 | 1.53M | 0 | 0 |
| Other Current Liabilities | 0 | -26.32M | 482K | 5.14M | 5.34M | 4.93M | 14K |
| Current Ratio | 12.27x | 4.40x | 6.62x | 6.40x | 12.14x | 2.48x | 5.35x |
| Quick Ratio | 12.27x | 4.40x | 6.62x | 6.40x | 12.14x | 2.48x | 5.35x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 35M | 35.08M | 35.59M | 35.43M | 9.63M | 5.53M | 1.53M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 4.28M | 3.6M | 1.27M |
| Capital Lease Obligations | 86K | 80K | 591K | 431K | 320K | 271K | 257K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 35M | 0 | 0 | 0 | 5.03M | 1.66M | 0 |
| Total Liabilities | 39.23M | 53.09M | 50.53M | 57.38M | 20.88M | 12.87M | 2.95M |
| Total Debt | 0 | 5.28M | 6.31M | 5.45M | 4.87M | 4.08M | 1.76M |
| Net Debt | -49.66M | -29.73M | -37.92M | -94.88M | -86M | -11.74M | -5.57M |
| Debt / Equity | 0.00x | 0.19x | 0.12x | 0.06x | 0.04x | 0.54x | 0.30x |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.69x | - | - | - | - | - | - |
| Interest Coverage | -34.27x | -57.66x | -92.33x | -424.85x | -69.78x | -42.90x | -109.77x |
| Total Equity | 12.68M | 27.75M | 51.18M | 86.04M | 118.37M | 7.62M | 5.84M |
| Equity Growth % | -210.16% | -45.79% | -40.52% | -27.31% | 1453.17% | 30.41% | - |
| Book Value per Share | 0.47 | 1.03 | 1.91 | 3.32 | 5.99 | 0.30 | 0.32 |
| Total Shareholders' Equity | 12.68M | 27.75M | 51.18M | 86.04M | 118.37M | 7.62M | 5.84M |
| Common Stock | 3.72M | 3.72M | 3.71M | 3.71M | 3.65M | 0 | 0 |
| Retained Earnings | -194.28M | -174.97M | -148.07M | -108.07M | -76.16M | -33.39M | -13.7M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -9.78M | -12.65M | -10.9M | -12.97M | -6.22M | -81K | -13K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LVTX stock.
As of 2024, LAVA Therapeutics N.V. (LVTX) had total assets of $80.8M including $79.3M in current assets.
LAVA Therapeutics N.V. (LVTX) carries total debt of $5.3M, offset by $76.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
LAVA Therapeutics N.V. (LVTX) has total shareholders' equity (book value) of $27.7M ($1.03 book value per share). Book value represents the net worth of the company belonging to common stock holders.
LAVA Therapeutics N.V. (LVTX) reported a current ratio of 4.40x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.